Cancer Management and Research (Nov 2020)
Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
Abstract
Peng-Fei Song, Ning Xu, Qin Li Department of Respiratory and Critical Care Medicine, The First People’s Hospital of Lian Yun Gang, Lian Yun Gang 222000, Jiangsu, People’s Republic of ChinaCorrespondence: Qin LiDepartment of Respiratory and Critical Care Medicine, The First People’s Hospital of Lian Yun Gang, 182 North Tongguan Road, Lian Yun Gang 222000, Jiangsu, People’s Republic of ChinaTel +86 18961325376Email [email protected]: This study was to investigate the efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) and the prognostic significance of common adverse reactions.Patients and Methods: A total of 79 elderly patients (≥ 60 years) with ES-SCLC who failed after at least two lines of previous systemic therapy were included. Baseline characteristics of the patients were collected. Follow-up was conducted regularly. Adverse reactions were documented. Survival curves were drawn using Kaplan–Meier method. Univariate analysis was assessed using log rank test, and multivariate analysis was adjusted by Cox regression analysis. Additionally, the prognostic significance of common adverse reactions was performed.Results: All of the 79 patients were available for evaluation of efficacy. Partial response (PR) was observed in 7 patients, stable disease (SD) was noted in 48 patients and progressive disease (PD) was confirmed in 24 patients. Consequently, the objective response rate (ORR) was 8.9% and disease control rate (DCR) was 69.6%. The median progression-free survival (PFS) of the 79 elderly patients with ES-SCLC was 3.0 months [95% confidence interval (CI): 2.02– 3.98]. The median overall survival (OS) was 7.1 months (95% CI: 5.07– 9.13). Safety profile demonstrated that the relatively common adverse reactions of the elderly patients with ES-SCLC receiving anlotinib treatment were hypertension (40.5%), hand-foot syndrome (HFS, 31.6%), diarrhea (27.8%), decreased appetite (20.3%), fatigue (17.7%) and weight loss (17.7%). Interestingly, the prognostic significance of common adverse reactions indicated that the median PFS of patients with hypertension and without hypertension was 4.35 and 2.95 months, respectively (P=0.01), and the median PFS of patients with HFS and without HFS was 4.20 and 2.95 months, respectively (P=0.03).Conclusion: The preliminary efficacy and safety of anlotinib in the treatment for elderly patients with previously treated ES-SCLC was satisfactory, and patients with hypertension and hand-foot syndrome might confer superior prognosis.Keywords: elderly small cell lung cancer, anlotinib, efficacy, safety, biomarker
